| 5.54 -0.05 (-0.89%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.79 | 1-year : | 17.28 |
| Resists | First : | 10.95 | Second : | 14.8 |
| Pivot price | 5.9 |
|||
| Supports | First : | 4.73 | Second : | 3.93 |
| MAs | MA(5) : | 5.61 |
MA(20) : | 6.23  |
| MA(100) : | 6.2 |
MA(250) : | 6.91 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4 |
D(3) : | 4 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 14.8 | Low : | 4.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TTNP ] has closed above bottom band by 22.6%. Bollinger Bands are 30.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.73 - 5.77 | 5.77 - 5.8 |
| Low: | 5.44 - 5.48 | 5.48 - 5.52 |
| Close: | 5.48 - 5.54 | 5.54 - 5.59 |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Mon, 09 Sep 2024
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Wed, 04 Sep 2024
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP - PR Newswire
Wed, 04 Sep 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPXX, PWUP, DECA, TTNP on Behalf of Shareholders - Longview News-Journal
Mon, 19 Aug 2024
TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
Mon, 19 Aug 2024
Titan Pharmaceuticals Embarks on Strategic Merger and Restructuring - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 700060 (%) |
| Held by Institutions | 45.4 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.09e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -237 % |
| Return on Assets (ttm) | 633.3 % |
| Return on Equity (ttm) | -172.7 % |
| Qtrly Rev. Growth | 3000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -312.71 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.49 |
| Dividend | 0 |
| Forward Dividend | 4630 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|